Eu Cosmetic Cpsr Pif Safety Assessment Service
A useful EU cosmetic CPSR/PIF safety-assessment service must deliver more than a signed certificate. Before a cosmetic is placed on the EU market, the responsible person (RP) must ensure that safety has been assessed and that a Cosmetic Product Safety Report (CPSR) is available within the Product Information File (PIF). Commissioning an assessor does not transfer the RP’s legal duties. This page explains the evidence hand-off, acceptance criteria and stop/go decisions for one defined formulation and its intended use.
Define the exact product and commissionable assessment
Start with the final quantitative formula, intended users, application site, exposure pattern, packaging and draft claims. A leave-on facial cream, rinse-off cleanser and product for children under three do not present interchangeable exposure assumptions. First confirm the product falls within the cosmetic definition in Article 2(1)(a); therapeutic claims or a different intended purpose can require a different regulatory analysis. Do not buy a generic CPSR template before product classification and formula ownership are clear.
Specify the deliverable: CPSR Parts A and B, plus the rest of the PIF
Article 10 and Annex I require a substantiated CPSR, not a bare declaration. Its Part A assembles safety information; Part B contains the qualified assessor’s scientific conclusion, reasoning, necessary warnings and credentials/approval. Article 11 requires the broader PIF, which the RP must keep up to date.
If an Annex I data item or study is considered unnecessary for this particular product, explain the omission expressly in Part A, and have the assessor repeat and validate the justification in Part B. Commission guidance 2013/674/EU does not create an exemption from safety assessment.
- CPSR Part A: precise qualitative/quantitative composition; physical/chemical properties and stability; microbiological quality; impurities, traces and packaging information; normal and reasonably foreseeable use; exposure to product and substances; toxicological profiles; undesirable effects; other relevant product information.
- CPSR Part B: safety conclusion (including any restrictions), warnings/instructions, reasoned assessment and the safety assessor’s name, address, qualifications, date and approval/signature.
- PIF beyond the CPSR: unambiguous product identification, manufacturing method and GMP-compliance statement, evidence substantiating claimed effects where justified, and relevant animal-testing data described in Article 11(2).
- Traceability: report version, formula identifier and concentration version, final pack variant, supporting-study references and any open data gaps should be recoverable by the RP and assessor.
- Do not treat a third-party “CPSR package” as an EU approval, a CE certificate or a CPNP notification. Notification is a separate RP step under Article 13.
Input-to-evidence matrix: what to supply before assessment
Use this as the service intake list. The last column is a practical evidence gate, not a claim that every product requires every laboratory test.
| Input from brand / manufacturer | Assessor’s decision it supports | If incomplete |
|---|---|---|
| Exact finished-formula ingredient percentages, chemical/INCI identities, functions and relevant raw-material composition and impurities | Screen substance restrictions and calculate exposure to ingredients | Hold the conclusion until exact composition and impurities are defensible. |
| Supplier specifications, available toxicology, impurities, allergens and relevant certificates | Evaluate each ingredient and quality of substances/mixtures | Request source records or justify a scientifically appropriate alternative. |
| Finished-product specifications, stability, packaging contact/compatibility data | Evaluate foreseeable shelf-life and migration/pack interaction | Determine whether targeted stability or pack evidence is needed. |
| Microbial specifications and preservation rationale; tests where appropriate | Address microbial risks for product type and users | Assessor decides if further microbiology or preservation efficacy evidence is needed. |
| Use instructions, application area, frequency, target population, warnings and label draft | Set exposure assumptions and safety-related warnings | Do not sign against invented uses or an unreviewed label. |
| Available complaint/adverse-effect history and related formulation experience | Assess reported undesirable effects and emerging risks | Disclose known signals and plan post-market review. |
Verify the EU RP, qualified Part B signatory and PIF access
The EU-established responsible person identified under Article 4 ensures compliance, keeps the PIF accessible at the address indicated on the label, and controls updates. The qualified safety assessor performs the Part B assessment; Article 10(2) requires a diploma or other evidence of formal qualifications following university-level theoretical and practical study in pharmacy, toxicology, medicine or a similar discipline, or a course recognised as equivalent by a Member State. A laboratory may generate data, and a document coordinator may compile the file, but neither activity alone equals a qualified Part B assessment. Ask for qualification evidence and establish the right to access underlying records, even if supplier formulas are handled confidentially. Under Article 11(1), the PIF must remain available for ten years after the last batch of the product was placed on the market.
For an imported cosmetic, Article 4(5) makes each importer the responsible person for the specific product it places on the market unless a person established in the EU accepts a written mandate. Establish who holds that role before contracting. Article 11(3) also requires the PIF to be readily accessible to the competent authority at the address on the label, with its information available in a language easily understood by the authorities of the Member State concerned; that does not mean automatic translation into every EU language.
Four outcome gates for commissioning and release
These are practical decisions derived from the need for a defensible report; they are not a statutory EU approval procedure.
‘Ready for assessor’ means the scientific review can start; it is not clearance to sell. Even with a favourable Part B, the responsible person must independently confirm the other applicable pre-market requirements, including ingredient restrictions, the complete PIF, labelling and CPNP notification.
If the formula contains nanomaterials, check separately whether Article 16 requires an additional pre-market notification; applicability and exceptions depend on the nanomaterial and its regulatory status. A standard Article 13 CPNP submission does not by itself resolve that question.
| Status | Evidence position | Safe next step |
|---|---|---|
| Ready for assessor | Identified final formula, use, packaging and sufficient scientific data | Commission Part A/B review and resolve written questions. |
| Data gap | Critical toxicology, composition, microbial or stability evidence missing | Collect targeted evidence; ask assessor to justify any proposed study. |
| Assessment restriction | Part B concludes safe only with specified use limits or warnings | Revise label/use or formula as directed and verify the assessed scenario matches the SKU. |
| Not safe / not supportable | Safety cannot be concluded for intended use | Do not place the product on the EU market on that assessment; reformulate or change evidence and reassess. |
Acceptance test for a commissioned CPSR/PIF service
- Freeze the version: give the assessor an identified formula, manufacturing/packaging variants and precise target users; record which SKUs share the assessment and why.
- Approve a gap memorandum: distinguish legally required report headings from case-specific data needed for the assessor’s conclusion; do not assume all challenge, patch or stability tests are universally mandatory.
- Review Part A references: check ingredient inputs, calculations, exposure assumptions, packaging and microbial rationale against actual supplier/product records.
- Verify Part B sign-off: check the explicit conclusion, any limits, warnings, scientific reasoning, qualifications, assessor identification and dated approval.
- Hand over a retrievable PIF index and update protocol to the RP; separately verify labelling and arrange CPNP notification before market placement.
Acceptance red flags: a PDF lacking Part B reasoning; a report for a materially different formula; an unsigned/unattributed assessment; unknown assessor credentials; unsupported “approved for all EU products” wording; missing supporting records; or a provider who does not state which PIF elements are outside the quote.
Change-control map: when a signed report needs review
The RP must keep the CPSR and PIF updated when relevant information changes. Not every alteration automatically requires new testing; decide and document materiality with the assessor.
| Change trigger | Reassessment question | Action |
|---|---|---|
| New ingredient, concentration or raw-material specification | Does toxicological profile or exposure change? | Screen restrictions and revise calculations/conclusion as appropriate. |
| New primary container, supplier or shelf-life claim | Could interaction, impurities or stability change? | Review packaging/quality evidence and commission targeted work if justified. |
| New usage, sensitive population or safety-related label claim | Would exposure or the safety conclusion differ? | Revisit assessed conditions and warnings before release. |
| Complaint trend, undesirable or serious undesirable effects, new substance restriction | Does emerging evidence overturn the safety reasoning? | Escalate to RP/assessor, update file and meet separate reporting/corrective duties where applicable. |
Where CPSR handover ends: RP appointment and CPNP filing
A CPSR is a central PIF component, not a complete market-access passport. The wider service-deliverables comparison belongs to the general CPSR/PIF services overview; strategic supplier selection and preliminary route questions belong to the CPSR/PIF consultant page. The actual portal submission belongs to the EU CPNP notification service. To commission the assessment, prepare intended-use and packaging specifications, the existing study inventory and the identity of the proposed RP; request a written gap list, a named qualified assessor, defined outputs and post-change review terms. Do not assume the provider becomes RP merely by preparing the CPSR.
For an initial quotation, a non-confidential product brief may suffice. Before a safety conclusion is issued, the qualified assessor needs the exact quantitative formula and necessary substance information through an agreed confidential channel; a redacted summary cannot substitute for safety data.
CPSR variants, confidential formulas and report sign-off: five FAQs
Can one CPSR cover several scents or shades?
Only if the assessor can substantiate the safety of every covered variant and the file identifies them. Different fragrance allergens, pigments, concentrations or exposure patterns may require variant-specific data or assessment; “one range” is not an automatic exemption.
Is a challenge test compulsory for every anhydrous product?
The Regulation requires safety evidence and microbiological assessment, not a universal named test for every formula. The assessor should document the product-specific microbial risk and explain whether a preservation efficacy study is relevant.
Can an assessor sign without receiving the full confidential recipe?
A defensible quantitative assessment requires sufficient exact composition and safety inputs. Confidential exchange directly with the assessor is possible by agreement, but withholding key concentrations prevents reliable exposure and ingredient evaluation.
Does a signed CPSR mean my product is registered or approved by the EU?
No. The CPSR is part of the RP-held PIF. CPNP notification under Article 13 is a separate, free portal process and is not a marketing authorisation.
What happens when the packaging or preservative changes after sign-off?
The RP and assessor must review whether the safety reasoning still applies; update the CPSR/PIF and obtain additional evidence if needed before relying on the amended assessment.
Official rules for EU CPSR, PIF and cosmetic notification
Legal baseline: Regulation (EC) No 1223/2009, consolidated text dated 18 May 2026 (check subsequent amendments); Commission Decision 2013/674/EU gives technical guidance, not a substitute for the law or assessor judgment.